Table 4.
Ongoing Clinical Trials of Novel Therapeutics in Atypical Teratoid/Rhabdoid Tumors
| NCT Number | Subtype | Recruitment | Phases | Type of intervention / target |
|---|---|---|---|---|
| NCT00089245 | Biologic | Recruiting | Phase 1 | I-131 monoclonal antibody 8H9 |
| NCT00445965 | Biologic | Active, not recruiting | Phase 2 | I-131 monoclonal antibody 3F8 |
| NCT02444546 | Biologic | Suspended | Phase 1 | Wild-type reovirus |
| NCT02962167 | Biologic | Recruiting | Phase 1 | Modified measles virus (MV-NIS) |
| NCT00003469 | SMI | Terminated | Phase 2 | Atengenal, astugenal (antineoplastons) |
| NCT00015899 | SMI | Completed | Phase 1 | Lonafarnib (Farnesyltransferase inhibitor) |
| NCT00217412 | SMI | Completed | Phase 1 | Vorinostat (HDAC inhibitor) |
| NCT00303940 | SMI | Completed | Phase 1 | Talabostat (dipeptidyl peptidase inhibitor / immune modulator) |
| NCT00326664 | SMI | Completed | Phase 1 | Cediranib (VEGF inhibitor) |
| NCT00572182 | SMI | Terminated | Phase 1 | MK-0752 (Gamma secretase, Notch inhibitor) |
| NCT00788125 | SMI | Active, not recruiting | Phase 1 / 2 | Dasatinib (multi-TK inhibitor) |
| NCT00939770 | SMI | Active, not recruiting | Phase 1 / 2 | Crizotinib (ALK, ROS1 inhibitor) |
| NCT00946335 | SMI | Completed | Phase 1 | Veliparib (PARP inhibitor) |
| NCT01076530 | SMI | Completed | Phase 1 | Vorinostat (HDAC inhibitor) |
| NCT01088763 | SMI | Terminated | Phase 1 | RO4929097 (Gamma-secretase, Notch inhibitor) |
| NCT02114229 | SMI | Recruiting | Phase 2 | Alisertib (aurora Kinase A inhibitor) |
| NCT03387020 | SMI | Not yet recruiting | Phase 1 | Ribociclib (CDK4/6 inhibitor) |
| NCT03434262 | SMI | Recruiting | Phase 1 | Ribociclib (CDK4/6 inhibitor) |
Abbreviations: ALK, anaplastic lymphoma kinase; CDK, cyclin-dependent kinase; SMI, small molecule inhibitor; HDAC, histone deacetylase; HSCT, hematopoietic stem cell transplantation; ID, identification; IT, intrathecal; MV-NIS, measles virus encoding human thyroidal sodium iodide symporter; PARP, poly (adenosine diphosphate-ribose) polymerase; ROS1, proto-oncogene tyrosine-protein kinase; SMI, submucosal invasion; TK, tyrosine kinase; VEGF, vascular endothelial growth factor.